Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2026-04-24 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 Annual General Meeting (AGM) of Northeast Pharmaceutical Group Co., Ltd. It includes voting results on various proposals such as the 2025 board work report, financial reports, profit distribution plan, appointment of auditors, and other corporate matters. The document also confirms the legality and validity of the meeting and resolutions, with legal opinions from a law firm. The content is focused on the shareholder meeting decisions and voting outcomes rather than the full annual report or financial statements themselves. The document length is about 5405 characters, which is sufficient for a detailed voting results announcement. Therefore, this document fits the category of "Declaration of Voting Results & Voting Rights Announcements (DVA)" rather than the full Annual Report (10-K) or other categories.
2026-04-24 Chinese
北京德恒律师事务所关于东北制药集团股份有限公司2025年度股东会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the 2025 Annual General Meeting (AGM) of Northeast Pharmaceutical Group Co., Ltd. It details the legality of the meeting's convening, attendance, voting procedures, and results. The document includes extensive information about the meeting's agenda, voting outcomes on various proposals including the annual report, financial statements, profit distribution, and other corporate matters. The document is not the AGM materials or presentations themselves but a legal opinion on the AGM process and results. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and validates the meeting's legality. The document length (9538 characters) and content confirm it is not a brief announcement or a full annual report but a detailed legal opinion on the AGM proceedings and voting results.
2026-04-24 Chinese
诉讼进展公告
Legal Proceedings Report Classification · 95% confidence The document is titled '诉讼进展公告' which translates to 'Litigation Progress Announcement'. It details the progress and outcome of a specific legal case involving the company, including court decisions and financial impact related to the litigation. There is no indication that this is a full audit report or annual report, nor is it a financial statement or earnings release. The content focuses on legal proceedings and updates on lawsuits. Therefore, the document fits the category of Legal Proceedings Report (LTR). The document length is short and it is not merely an announcement of a report but contains substantive information about the legal case and its impact.
2026-04-24 Chinese
2025年度独立董事述职报告（黄永维）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 of a company. It details the independent director's personal background, attendance at board and shareholder meetings, participation in committees, communication with auditors, and evaluation of company governance and operations during the year. It also discusses the director's exercise of duties, involvement in key decisions such as appointment of senior management, audit firm changes, and related party transactions. The document is a detailed report on the independent director's annual duties and activities rather than a general annual report or financial statement. This type of document fits best under the category of Board/Management Information (MANG), as it relates to board member activities and governance rather than full financial reporting or other categories.
2026-04-02 Chinese
2025年度独立董事述职报告（姚辉-已离任）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Work Report" for the year 2025 for Northeast Pharmaceutical Group Co., Ltd. It details the independent director's personal background, attendance at board and committee meetings, exercise of duties, communication with auditors, and evaluation of company governance and operations during the year. The content focuses on the independent director's activities and oversight rather than presenting financial statements or audit results. It is a detailed report on board/management information, specifically the independent director's annual report on their duties and observations. It is not an annual report (10-K), audit report (AR), or regulatory filing (RNS). The document length is 4529 characters, which is substantive and contains detailed information about board activities and management oversight. Therefore, the best fitting category is Board/Management Information (MANG).
2026-04-02 Chinese
关于2025年度会计师事务所履职情况评估报告及董事会审计委员会履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm and the audit committee's supervision for the fiscal year 2025. It discusses the appointment and assessment of the external auditor (an accounting firm) for the 2025 annual financial report and internal control audit. It includes details about the auditor's qualifications, audit scope, communication with management, and the audit committee's oversight activities. The document contains no actual financial statements or detailed financial data but is a report on the audit process and oversight. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory audits, excluding full annual reports. The document length is 2600 characters, which is relatively short but contains substantive audit evaluation content rather than just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2025
2026-04-02 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.